The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
==== Other sex-hormonal agents ==== Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – atrophic vaginitis, dyspareunia [142] Testosterone propionate (TP; Synandrol; Synerone) – androgen (androgen receptor agonist) – decreased libido [143] Tibolone (Livial) – androgen, estrogen, and progestogen – atrophic vaginitis, dyspareunia, low sexual desire [144] Triptorelin (Arvekap; AY-25650; BIM-21003; BN-52014; CL-118532; Debio-8200; Debio-8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptoreline; Tryptorelin; WY-42422) – gonadotropin-releasing hormone (GnRH) receptor agonist – paraphilias [145]
The two substrates of this enzyme are (R)-2-hydroxystearic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 2-oxostearic acid, reduced NADH, and a proton. This reaction is important in fatty acid metabolism. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R)-2-hydroxystearate:NAD+ oxidoreductase. Other names in common use include D-2-hydroxy fatty acid dehydrogenase, and 2-hydroxy fatty acid oxidase.
NH4CO2NH2 ⇌ CO(NH2)2 + H2O (ΔH = 15.5 kJ/mol at 160–180 °C (320–356 °F)) The overall conversion of NH3 and CO2 to urea is exothermic, with the reaction heat from the first reaction driving the second. The conditions that favor urea formation (high temperature) have an unfavorable effect on the carbamate formation equilibrium. The process conditions are a compromise: the ill-effect on the first reaction of the high temperature (around 190 °C (374 °F)) needed for the second is compensated for by conducting the process under high pressure (1.4–1.75 MPa (203–254 psi)), which favors the first reaction. Although it is necessary to compress gaseous carbon dioxide to this pressure, the ammonia is available from the ammonia production plant in liquid form, which can be pumped into the system much more economically. To allow the slow urea formation reaction time to reach equilibrium, a large reaction space is needed, so the synthesis reactor in a large urea plant tends to be a massive pressure vessel.
Sources: en.wikipedia.org
==== Lithium levels ==== According to Stahl's Prescriber's Guide, target concentrations for acute mania should be 1.0–1.5 mEq/L. 0.6–1.0 mEq/L for depression, and 0.7–1.0 mEq/L for long-term maintenance of bipolar disorder. In the elderly, lower doses and lower lithium levels (<0.6 mEq/L) are often adequate and advisable. The Maudsley and Ghaemi prescriber's guides recommend a slightly lower lithium level of 0.8–1.0 mmol/L for acute mania. For the maintenance treatment of bipolar disorder, the International Society for Bipolar Disorders (ISBD) and International Study Group on Lithium (ISGL) guidelines recommend lithium levels of 0.6–0.8 mmol/L. In the case of good response but poor tolerance, the guidelines recommend a level of 0.4–0.6 mmol/L. In the case of insufficient response but good tolerance, the guidelines recommend a level of 0.8–1.0 mmol/L. For the maintenance treatment of the elderly, the ISBD and ISGL guidelines recommend a more conservative approach of levels of 0.4–0.6 mmol/L, with the option to go up to 0.7 or 0.8 mmol/L at ages 65–79, and up to a maximum of 0.7 mmol/L over age 80. As a result of lithium's narrow therapeutic index, toxic effects can occur at serum concentrations close to therapeutic levels, necessitating close monitoring during treatment. Initially, levels are measured every 1–2 weeks until the desired serum concentration is achieved, then every 2–3 months for the first 6 months. Once stable, levels are measured every 6–12 months. Levels of 1.2–1.5 mmol/L are considered borderline toxic. Levels above 1.5 mmol/L are considered toxic.
The curricula address subjects such as the biology of ageing, biomarkers, preventive medicine, healthspan, clinical assessment and the translation of ageing research into healthcare. The doctoral partnership with Ovidius University of Constanța began with a 2026 intake. The programme is described as a research doctorate in medicine with a specialization in longevity sciences and is not a physician qualification. Ovidius University is the degree-awarding institution. Dominik Thor serves as president of GCLS and professor of pharmacy. Luiza Spiru has held academic responsibilities within the institution, including involvement in longevity-medicine education and the Ovidius University doctoral collaboration.
== Books == Anabolic Reference Guide. Mile High Publishing, 1991. Sports Supplement Review. Mile High Publishing, 1997. Body-for-LIFE: 12 Weeks to Mental and Physical Strength. HarperCollins, 1999. ISBN 0-06-019339-5 Body for Life Success Journal. HarperCollins, 2002. ISBN 0-06-051559-7 Eating for Life: Your Guide to Great Health, Fat Loss and Increased Energy! High Point Media, 2003. ISBN 0-9720184-1-7 Transformation: A Path from Physical to Spiritual Well-Being. Hay House, 2010. ISBN 978-1-4019-1176-8
Pluralism and regulation of the media, such as through 'the licensing of broadcasting, television or cinema enterprises', have long been seen as essential to protect freedom of opinion and expression, to ensure that citizens have a more equal voice, and ultimately to support the universal 'right to take part in the government'. In almost all member states there is a well funded public, and independent broadcaster for TV and radio, and there are common standards for all TV and radio, which are designed to support open, fact-based discussion and deliberative democracy. However, the same standards have not yet been applied to equivalent internet television, radio or "social media" such as the platforms controlled by YouTube (owned by Alphabet), Facebook or Instagram (owned by Meta), or Twitter (owned by Elon Musk), all of which have spread conspiracy theories, discrimination, far-right, extremist, terrorist, and hostile military content.
Sources: en.wikipedia.org
=== Parkinson's disease === Mesocarb, has been under development for the treatment of Parkinson's disease since 2016. As of February 2023, it is in phase 1 clinical trials for this indication. However, no recent development has been reported. Mesocarb's active enantiomer armesocarb is also under development.
In physics and chemistry, binding energy is the smallest amount of energy required to remove a particle from a system of particles or to disassemble a system of particles into individual parts. In the former meaning the term is predominantly used in condensed matter physics, atomic physics, and chemistry, whereas in nuclear physics the term separation energy is used. A bound system is typically at a lower energy level than its unbound constituents. According to relativity theory, a ΔE decrease in the total energy of a system is accompanied by a decrease Δm in the total mass, where Δmc2 = ΔE. There are several types of binding energy, each operating over a different distance and energy scale. The smaller the size of a bound system, the higher its associated binding energy.
MIPOL1 (Mirror Image Polydactyly 1), also known as CCDC193 (Coiled-coil domain containing 193), is a protein that in humans is encoded by the MIPOL1 gene. Mutation of this gene is associated with mirror-image polydactyly (also known as Laurin-Sandrow syndrome.) in humans, which is a rare genetic condition characterized by mirror-image duplication of digits. MIPOL1 is also known as CCDC193 (Coiled-coil domain containing 193). The MIPOL1 gene is located at 14q13.3-q21.1 on the plus strand, spanning base pairs 37,197,888 to 37,579,207 (in the human GRCh38 primary assembly, length: 381,320 base pairs), consisting of 15 exons and 11 introns. Some notable genes in its neighborhood include SLC25A21 (mutation of this gene causes synpolydactyly) and FOXA1. MIPOL1 has at least 15 known splice isoforms produced by alternative splicing. The unmodified MIPOL1 protein isoform 1 in humans has an isoelectric point of 5.6 and molecular weight 51.5 kDa. Relative to other human proteins, MIPOL1 consists of unusually low amounts of Proline and Glycine and higher amounts of Glutamic acid and Glutamine.
== Health concerns == For introduction of radionuclides into an organism, ingestion is the most important route. Insoluble compounds are not absorbed from the gut and cause only local irradiation before they are excreted. Soluble forms however show wide range of absorption percentages.
== Example case: bacterial plasmid subcloning == In this example, a gene from mammalian gene library will be subcloned into a bacterial plasmid (destination platform). The bacterial plasmid is a piece of circular DNA which contains regulatory elements allowing for the bacteria to produce a gene product (gene expression) if it is placed in the correct place in the plasmid. The production site is flanked by two restriction enzyme cutting sites "A" and "B" with incompatible sticky ends. The mammalian DNA does not come with these restriction sites, so they are built in by overlap extension PCR. The primers are designed to put the restriction sites carefully, so that the coding of the protein is in-frame, and a minimum of extra amino acids is implanted on either side of the protein. Both the PCR product containing the mammalian gene with the new restriction sites and the destination plasmid are subjected to restriction digestion, and the digest products are purified by gel electrophoresis. The digest products, now containing compatible sticky ends with each other (but incompatible sticky ends with themselves) are subjected to ligation, creating a new plasmid which contains the background elements of the original plasmid with a different insert. The plasmid is transformed into bacteria and the identity of the insert is confirmed by DNA sequencing.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.